AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 14 - (NewsRx.com & NewsRx.net) -- Recombinant BCG DNA vaccines and gene immunotherapy treat bladder cancer.
According to a study from Taiwan, "intravesical immunotherapy with live Mycobacterium bovis bacillus Calmette-Guerin (BCG) is the treatment of choice for superficial bladder cancers. Nevertheless, a significant proportion of patients do not respond to this therapy, and adverse effects are common. Here, we report the cloning of recombinant mycobacterial DNA vaccines and demonstrate the ability of multicomponent and multisubunit DNA vaccines to enhance Th1-polarized cytokine-mediated responses as well as effector cell responses."
"Splenocytes from immunized groups of mice were restimulated in vitro and examined for cytotoxicity against murine bladder tumor (MBT-2) cells. We used four combined recombinant BCG DNA vaccines (poly-rBCG) for electroporative gene immunotherapy (EPGIT) in vivo, and found that tumor growth was significantly inhibited and mouse survival was prolonged," said C.F. Lee and colleagues, Tri-Service General Hospital, Department of Surgery.
"Increased immune cell infiltration and induction of apoptosis were noted after treatment with poly-rBCG alone, with the murine interleukin-12 (mIL-12) vaccine alone, and, most significantly, ...
Source: HighBeam Research, Recombinant BCG DNA vaccines and gene immunotherapy treat bladder...